No Data
Benchmark Co. Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $15
Benchmark Co. analyst Bruce Jackson maintains $Humacyte(HUMA.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 28.9% and a tot
Humacyte Shares Are Continuing Higher After the Company on Monday Announced It Was Granted Regenerative Medicine Advanced Therapy Designation by the FDA for Patients With Advanced Peripheral Artery Disease.
Humacyte Shares Are Continuing Higher After the Company on Monday Announced It Was Granted Regenerative Medicine Advanced Therapy Designation by the FDA for Patients With Advanced Peripheral Artery Di
Humacyte (HUMA) Gets a Buy From Benchmark Co.
Why Humacyte Stock Is Trading 15% Higher Monday
Humacyte, Inc. (NASDAQ:HUMA) is moving higher on Monday after receiving the Food and Drug Administration's Regenerative Medicine Advanced Therapy (RMAT) designation for its Acellular Tissue Engineered
Humacyte Stock Rallies 19% on FDA RMAT Designation
Humacyte Announces Third RMAT Designation By FDA For ATEV - Quick Facts